These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2599073)

  • 21. Potency ratio for the inhibition of 3H-QNB and 3H-cis-methyldioxolane binding predicts agonist or antagonist activity on muscarinic receptors.
    Moret C; Pastrie I; Briley M
    Methods Find Exp Clin Pharmacol; 1988 Oct; 10(10):619-21. PubMed ID: 3236936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac autonomic receptors: effect of long-term experimental diabetes.
    Latifpour J; McNeill JH
    J Pharmacol Exp Ther; 1984 Jul; 230(1):242-9. PubMed ID: 6086879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of monoclonal antibodies to the beta-adrenergic antagonist alprenolol as models of the receptor binding site.
    Sawutz DG; Sylvestre D; Homcy CJ
    J Immunol; 1985 Oct; 135(4):2713-8. PubMed ID: 2993414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative distribution densities of cholinergic and adrenoceptor structures in the central part of the sinoatrial node in rat heart.
    Sutyagin PV; Kalinina EE; Pylaev AS
    Bull Exp Biol Med; 2005 Jul; 140(1):92-5. PubMed ID: 16254630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methodological aspects of receptor research: problems in the assessment of specific and non-specific binding of 3H-dihydroalprenolol to bovine lung membranes.
    Richardson A; Nahorski SR
    Eur J Respir Dis Suppl; 1984; 135():114-23. PubMed ID: 6329797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Solubilization by various detergents, of the muscarinic cholinoreceptor and its complex with quinuclidinyl benzilate].
    Rinken AA; Langel IuL; Iarv IaL
    Biokhimiia; 1987 Feb; 52(2):303-10. PubMed ID: 3567252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Displacement of [3H]dihydroalprenolol binding from rat heart and lung by acebutolol, diacetolol and D-diacetolol.
    Pong SF; Tinkham CL
    J Pharm Pharmacol; 1983 Mar; 35(3):198-9. PubMed ID: 6132987
    [No Abstract]   [Full Text] [Related]  

  • 28. In vivo effect of methyl-quinuclidinyl-benzylate on myocardial beta-adrenoceptor density.
    Valette H; Syrota A; Fuseau C; Brutesco C
    Eur J Pharmacol; 1996 Jun; 306(1-3):133-8. PubMed ID: 8813625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysosomotropic behavior of adrenergic antagonists in interactions with human neutrophils.
    Styrt B; Klempner MS
    Biochem Pharmacol; 1988 Feb; 37(3):435-41. PubMed ID: 2892495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific and unspecific binding of [3H](--)dihydroalprenolol to cardiac tissue.
    Krawietz W; Erdmann E
    Biochem Pharmacol; 1979 Apr; 28(8):1283-8. PubMed ID: 444294
    [No Abstract]   [Full Text] [Related]  

  • 31. [Changes in the activity of lysosomal enzymes and in the indices of cardiac contractile function in experimental diphtheria poisoning in rabbits].
    Frolov VA; Shkirmante BK; Kazanskaia TA
    Patol Fiziol Eksp Ter; 1990; (2):8-10. PubMed ID: 2381754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of 3H-dihydroalprenolol and 3H-dihydroergocryptine in tissue of rat and frog.
    Kempson SA; Marinetti GV
    Comp Biochem Physiol C Comp Pharmacol; 1979; 63C(1):177-81. PubMed ID: 37035
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of myocardial uptake and distribution of thallium-201 and two prototype receptor-binding radiopharmaceuticals in the normal and ischemic canine heart.
    Eckelman WC; Alter WA; Grissom MP; Vieras F; Phillips J; Eng R; Gibson RE; Reba RC
    Int J Nucl Med Biol; 1984; 11(3-4):287-90. PubMed ID: 6530347
    [No Abstract]   [Full Text] [Related]  

  • 34. [Alterations in lysosomal enzymes in rat myocardium following immunization].
    Laufer A; Fildes M
    Harefuah; 1976 Jun; 90(11):501-4. PubMed ID: 964742
    [No Abstract]   [Full Text] [Related]  

  • 35. In vivo and in vitro characteristics of the N-methyl derivative of [125I]3-quinuclidinyl 4-iodobenzilate.
    Gibson RE; Coenen HH; Jagoda E; Reba RC; Eckelman WC
    Int J Nucl Med Biol; 1984; 11(2):167-9. PubMed ID: 6480260
    [No Abstract]   [Full Text] [Related]  

  • 36. The prevention of an artifact in receptor binding assay by an improved technique.
    Hung CR; Hong JS; Bondy SC
    Life Sci; 1982 May; 30(20):1713-20. PubMed ID: 6285105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of iodine-125 labeled 3-quinuclidinyl 4'-iodobenzilate.
    Kabalka GW; Gai YZ; Mathur S
    Int J Rad Appl Instrum B; 1989; 16(4):359-60. PubMed ID: 2777574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interaction of anticholinesterases and diazepam in the treatment of anticholinergic syndrome in dogs.
    Fusek J; Herink J; Koupilová M; Patocka J; Bajgar J; Hrdina V
    Act Nerv Super (Praha); 1979 Oct; 21(3):183-4. PubMed ID: 517099
    [No Abstract]   [Full Text] [Related]  

  • 39. Changes in cytoplasmic and lysosomal enzyme activities in cultured rat heart cells: the relationship to cell differentiation and cell population in culture.
    Yagev S; Heller M; Pinson A
    In Vitro; 1984 Dec; 20(12):893-8. PubMed ID: 6530225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The crystal and molecular structure of quinuclidinyl benzilate hydrobromide.
    Meyerhöffer A; Carlström D
    Acta Crystallogr B Struct Crystallogr Cryst Chem; 1969 Jun; 25(6):1119-26. PubMed ID: 5819636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.